FM AUGUST 2018 ISSUE1 - digital edition
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
IQWave TM<br />
the next generation of electrochemotherapy devices<br />
The IQWave TM represents the next generation of electrochemotherapy devices with its effective and flexible treatment<br />
capabilities. It has been developed to achieve positive clinical outcomes on a level that was not possible in the past.<br />
Potent treatment<br />
The IQWave TM system enhances the effects of the chemotherapeutic<br />
substance by opening up small pores in the<br />
tumour cells, allowing the injected chemotherapeutic<br />
substance direct access to the DNA of the targeted cells.<br />
Combined with the coagulation effect created by the high<br />
voltage electric field the cancer cells go into rapid necrosis.<br />
Since electrochemotherapy normally can be performed under<br />
local anaesthesia and light sedation, it is rather painless as well<br />
time efficient. A complete treatment only takes 15 - 25 mins.<br />
Indications<br />
The current protocol for electrochemotherapy was established<br />
in 2006 by the ESOPE* study. The current indications for<br />
treatment with electrochemotherapy are.<br />
• Head and neck squamous cell carcinoma<br />
• Malignant melanoma<br />
• Basal cell carcinoma<br />
• Adenocarcinoma of the breast and salivary gland<br />
• Hypernephroma<br />
• Kaposi sarcoma<br />
• Transitional cell carcinoma<br />
*European Standard Operating Procedures of Electrochemotherapy<br />
.................................................................................................................................................................................................................................<br />
Scandinavian Chemotech AB, Baltzarsgatan 25, 211 36 Malmö, Sweden. Email : india@chemotech.se • www.chemotech.se
Change language